Naxitamab for high-risk or relapsed neuroblastoma in children
Treatments studied
Part of Cancer clinical trials.
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child has been diagnosed with high-risk neuroblastoma (including relapsed or hard-to-treat forms).
- You are at least 1 year old.
- If you are sexually active, you agree to use effective birth control during treatment.
- If you have started menstruating, you must have a negative pregnancy test and not be pregnant or breastfeeding.
- You have not had a severe allergic reaction to anti-GD2 antibodies or GM-CSF in the past.
- You are not currently taking another experimental drug (or have taken one in the last 4 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This study tests two drugs, tipifarnib and naxitamab, given together for children and young adults whose neuroblastoma has come back or did not go away with standard treatment. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
This trial tests a new combination of medicines for children with high-risk neuroblastoma that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.